1. What Happened?

Kwangdong Pharmaceutical reported Q2 2025 revenue of KRW 425.2 billion (+12% YoY), operating profit of KRW 4.5 billion (+36% YoY), and net profit of KRW 2.3 billion (-44% YoY). While revenue and operating profit beat market expectations, net profit declined.

2. Why Did This Happen?

Positive Factors: Robust growth in the F&B segment (Samdasoo, Vita500) and new licensing agreements in the ETC segment drove revenue and operating profit growth.

Negative Factors: Increased R&D expenses, marketing costs, and potentially one-off expenses contributed to the decline in net profit. Imbalanced capacity utilization in the F&B segment (overloaded food factory, low GMP factory utilization) also affected cost competitiveness.

3. What’s Next?

Kwangdong Pharmaceutical’s stable business portfolio and new business expansions point towards continued growth. However, addressing the decline in net profit, improving R&D investment efficiency, optimizing production capacity, and managing foreign exchange and interest rate risks are crucial.

4. What Should Investors Do?

  • Closely monitor the upcoming detailed earnings release and management’s explanation for the decline in net profit.
  • Carefully evaluate R&D investment strategies, the performance of new businesses (such as the solar power project), and foreign exchange and interest rate risk management strategies.
  • Make informed investment decisions based on a comprehensive assessment of Kwangdong Pharmaceutical’s growth potential and risks from a long-term perspective.